Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 22, 2009, Pages 6368-6372

  Burgey, Christopher S ^a   Potteiger, Craig M ^a   Deng, James Z ^a   Mosser, Scott D ^a   Salvatore, Christopher A ^a   Yu, Sean ^a   Roller, Shane ^a   Kane, Stefanie A ^a   Vacca, Joseph P ^a   Williams, Theresa M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Calcitonin gene related peptide; CGRP; CGRP receptor antagonists; Migraine

Indexed keywords

AZABENZIMIDAZOLONE; AZEPANONE; BENZOXAZINONE DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; HYDANTOIN; IMIDAZOLE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDAZINONE DERIVATIVE; PYRIDONE DERIVATIVE; QUINOLONE; SPIROAZABENZOXAZINONE; SPIRONAPHTHYRIDINONE; SPIROPIPERIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEPROTECTION REACTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RAT;

AMINO ACID SEQUENCE; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CIRCULAR DICHROISM; CLONING, MOLECULAR; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PIPERIDINES; PROTEIN BINDING; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71049116463     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.066     Document Type: Article

References (25)

1. Wackenfors A., Jarvius M., Ingemansson R., Edvinsson L., and Malmsjo M. J. Cardiovasc. Pharmacol. 45 (2004) 476
2. Durham P.L., and Russo A.F. Pharmacol. Ther. 94 (2002) 77
3. Edvinsson L. Exp. Opin. Ther. Targets 7 (2003) 377
4. Durham P.L. N. Engl. J. Med. 350 (2004) 1073
5. Olesen J., Diener H.-C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., Pollentier S., and Lesko L. N. Engl. J. Med. 350 (2004) 1104
6. Petersen K.A., Birk S., Lassen L.H., Krusse C., Jonassen O., Lesko L., and Olesen J. Cephalalgia 25 (2004) 139
7. Williams T.M., Burgey C.S., and Salvatore C.A. Prog. Med. Chem. 47 (2009) 1
8. Paone D.V., Shaw A.W., Nguyen D.N., Burgey C.S., Deng Z.J., Kane S.A., Koblan K.S., Salvatore C.A., Hershey J.C., Wong B., Roller S.G., Miller-Stein C., Graham S.L., Vacca J.P., and Williams T.M. J. Med. Chem. 50 (2007) 5564
9. Salvatore C.A., Hershey J.C., Corcoran H.A., Fay J.F., Johnston V.K., Moore E.L., Mosser S.D., Burgey C.S., Paone D.V., Shaw A.W., Graham S.L., Vacca J.P., Williams T.M., Koblan K.S., and Kane S.A. JPET 324 (2008) 416
10. Burgey C.S., Paone D.V., Shaw A.W., Deng J.Z., Nguyen D.N., Potteiger C.M., Graham S.L., Vacca J.P., and Williams T.M. Org. Lett. 10 (2008) 3235
11. Ho T.W., Mannix L., Fan X., Assaid C., Furtek C., Jones C., Lines C., and Rapoport A. Neurology 70 (2008) 1305
12. Ho T.W., Ferrari M.D., Dodick D.W., et al. Lancet 372 (2008) 2115
13. Roller S., Cui D., Laspina C., Miller-Stein C., Rowe J., Wong B., and Prueksaritanont T. Xenobiotica 39 (2009) 33
14. Burgey C.S., Stump C.A., Nguyen D.N., Deng J.Z., Quigley A.G., Norton B.R., Bell I.M., Mosser S.D., Salvatore C.A., Rutledge R.Z., Kane S.A., Koblan K.S., Vacca J.P., Graham S.L., and Williams T.M. Bioorg. Med. Chem. Lett. 16 (2006) 5052
15. For the details of these assays, see: Bell, I. M.; Graham, S. L.; Williams, T. M.; Stump, C. A. WO 2004/087649.
16. Williams T.M., Stump C.A., Nguyen D.N., Quigley A.G., Bell I.M., Gallichio S.N., Zartman C.B., Wan B.-L., Kunapuli P., Kane S.A., Koblan K.S., Mallee J.J., Mosser S.D., Rutledge R.Z., Salvatore C., Graham S.L., and Vacca J.P. Bioorg. Med. Chem. Lett. 16 (2006) 2595
17. For the details of the chemistry, see: Burgey, C. S.; Deng, Z. J.; Potteiger, C.; Williams, T. M. WO 2006/041830 A2.
18. Burgey, C. S.; Paone, D. V.; Shaw, A. W.; Nguyen, D. N.; Deng, Z. J.; Vacca, J. P.; Selnick, H. G.; Williams, T. M.; Potteiger, C. WO 2006/044504 A2.
19. Davies A.J., Brands K.M.J., Cowden C.J., Dolling U.-H., and Lieberman D.R. Tetrahedron Lett. 45 (2004) 1721
20. Ortho metalation/cyclization attempts without the chlorine group were unsuccessful.
21. In situ cyclization via the use of a carbamate protecting group were essential, as attempted deprotection of amides led to dehydration: for example, {A figure is presented}.
22. Wu J., Wu H., Wei S., and Dai W.-M. Tetrahedron Lett. 45 (2004) 4401 Produced a 4: 1 mixture of product: SM
23. Attempts to affect the desired cyclization from i instead produced 5-exo-trig product ii.{A figure is presented}.
24. Littke A.F., and Fu G.C. J. Am. Chem. Soc. 123 (2001) 6989
25. Coe, J. W. Org. Lett. 2000, 26, 4205; attempts to make this target by a Heck spirocyclization led instead to the 6-endo-trig byproduct v.{A figure is presented}.